The methods comprise administration of stibonic acid or diphenyl compounds that disrupt viral nucleocapsid binding to nucleic acids.
This degradation by viral components such as HIV-1 nucleocapsid protein renders inhibitory RNA aptamers generally ineffective in vivo.
